Protocol Ledger

NCT06124157 · Phase II · RECRUITING

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chrom

Interventional Phase II clinical trial protocol NCT06124157 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-05-30 Enrollment: 222 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06124157
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)222 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06124157
Protocol FieldVerified Registry Value
NCT IdentifierNCT06124157
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment222 participants (ESTIMATED)
Registered Start Date2025-05-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI